Form 10-Q August 02, 2016
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2016
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE $^{\rm o}$ ACT OF 1934
FOR THE TRANSITION PERIOD FROM TO
COMMISSION FILE NUMBER: 814-00802
HORIZON TECHNOLOGY FINANCE CORPORATION
(Exact name of registrant as specified in its charter)

27-2114934

312 Farmington Avenue Farmington, CT

DELAWARE

06032

(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (860) 676-8654

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes b No o.

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer" and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o Accelerated filer b Non-accelerated filer o Smaller Reporting Company o (Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No b .

As of August 2, 2016, the Registrant had 11,548,564 shares of common stock, \$0.001 par value, outstanding.

HORIZON TECHNOLOGY FINANCE CORPORATION

FORM 10-Q

TABLE OF CONTENTS

		Page
PART I		
Item 1.	Consolidated Financial Statements	3
	Consolidated Statements of Assets and Liabilities as of June 30, 2016 and December 31, 2015	
	(unaudited)	3
	Consolidated Statements of Operations for the three and six months ended June 30, 2016 and 2015	
	(unaudited)	4
	Consolidated Statements of Changes in Net Assets for the six months ended June 30, 2016 and 2015	5
	(unaudited)	5
	Consolidated Statements of Cash Flows for the six months ended June 30, 2016 and 2015 (unaudited)	6
	Consolidated Schedules of Investments as of June 30, 2016 and December 31, 2015 (unaudited)	7
	Notes to the Consolidated Financial Statements (unaudited)	18
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	37
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	50
Item 4.	Controls and Procedures	51
PART I	T	
		52
	<u>Legal Proceedings</u>	
	Risk Factors	52
	Unregistered Sales of Equity Securities and Use of Proceeds	52
	Defaults Upon Senior Securities	52
Item 4.	Mine Safety Disclosures	52
Item 5.	Other Information	52
Item 6.	<u>Exhibits</u>	52
	<u>Signatures</u>	53
EX-10.1		
EX-31.1		
EX-31.2		
EX-32.1		
EX-32.2		

PART I: FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Statements of Assets and Liabilities (Unaudited)

(Dollars in thousands, except share and per share data)

	June 30,	December 31,
	2016	2015
Assets		
Non-affiliate investments at fair value (cost of \$243,221 and \$255,494, respectively)	\$233,266	\$ 250,267
(Note 4)	. ,	
Investments in money market funds	16 200	285
Cash Restricted investments in money money money for founds	16,280	20,765
Restricted investments in money market funds Interest receivable	— 8,114	1,091 6,258
Other assets	2,259	2,230
Total assets	\$259,919	\$ 280,896
Total assets	Ψ237,717	Ψ 200,070
Liabilities		
Borrowings (Note 6)	\$100,502	\$ 114,954
Distributions payable	3,984	3,980
Base management fee payable (Note 3)	406	385
Incentive fee payable (Note 3)	1,027	1,028
Other accrued expenses	770	798
Total liabilities	106,689	121,145
Commitments and Contingencies (Note 7)		
Net assets		
Preferred stock, par value \$0.001 per share, 1,000,000 shares authorized, zero shares issued and outstanding as of June 30, 2016 and December 31, 2015	_	_
Common stock, par value \$0.001 per share, 100,000,000 shares authorized, 11,661,531 and 11,648,594 shares issued and 11,548,149 and 11,535,212 shares	12	12

outstanding as of June 30, 2016 and December 31, 2015, respectively	
Paid-in capital in excess of par	179,833 179,707
Distributions in excess of net investment income	(1,063) (2,006)
Net unrealized depreciation on investments	(9,955) (5,227)
Net realized loss on investments	(15,597) (12,735)
Total net assets	153,230 159,751
Total liabilities and net assets	\$259,919 \$ 280,896
Net asset value per common share	\$13.27 \$ 13.85

See Notes to Consolidated Financial Statements

Consolidated Statements of Operations (Unaudited)

(Dollars in thousands, except share and per share data)

	For the Three Months Ended June 30,		1	For the Six M June 30,		Months Ended		
	2016		2015		2016		2015	
Investment income								
Interest income on non-affiliate investments	\$8,788		\$6,599		\$17,790		\$13,161	
Prepayment fee income on non-affiliate investments	263		208		429		728	
Fee income on non-affiliate investments	41		50		170		234	
Total investment income	9,092		6,857		18,389		14,123	
Expenses								
Interest expense	1,512		1,263		3,046		2,850	
Base management fee (Note 3)	1,247		1,146		2,531		2,177	
Performance based incentive fee (Note 3)	1,027		722		2,126		1,458	
Administrative fee (Note 3)	275		309		556		577	
Professional fees	343		287		844		718	
General and administrative	261		299		462		559	
Total expenses	4,665		4,026		9,565		8,339	
Management and performance based incentive fees waived (Note 3)			(67)	_		(67)
Net expenses	4,665		3,959		9,565		8,272	
Net investment income before excise tax	4,427		2,898		8,824		5,851	
(Credit) provision for excise tax	(85)	10		(85)	20	
Net investment income	4,512		2,888		8,909		5,831	
Net realized and unrealized loss on investments								
Net realized loss on investments	(876)	(29)	(2,862)	(259)
Net unrealized (depreciation) appreciation on investments	(3,714)	(1,114)	(4,728)	18	
Net realized and unrealized loss on investments	(4,590)	(1,143)	(7,590)	(241)
Net (decrease) increase in net assets resulting from operations	\$(78)	\$1,745		\$1,319		\$5,590	
Net investment income per common share	\$0.39		\$0.25		\$0.77		\$0.54	
Net (decrease) increase in net assets per common share	\$(0.01)	\$0.15		\$0.11		\$0.52	
Distributions declared per share	\$0.345		\$0.345		\$0.69		\$0.69	
Weighted average shares outstanding	11,544,412	2	11,632,724	1	11,541,20	8	10,725,004	ŀ

See Notes to Consolidated Financial Statements

Consolidated Statements of Changes in Net Assets (Unaudited)

(Dollars in thousands, except share data)

	Common Sto	ock	Paid-In Capital in Excess of	Distributio in Excess of Net Investment	Unrealized Depreciation	Realized	Total Net
	Shares	Amour	ntPar	Income	Investment	s Investments	Assets
Balance at December 31, 2014	9,628,124	\$ 10	\$155,240	\$ (1,102) \$ (4,737		\$138,248
Issuance of common stock, net of offering costs	2,000,000	2	26,657	_	_	_	26,659
Net increase in net assets resulting from operations			_	5,831	18	(259) 5,590
Issuance of common stock under dividend reinvestment plan	7,356	_	102	_	_	_	102
Distributions declared	_			(7,797) —		(7,797)
Reclassification of permanent tax differences (Note 2)	_	_	(971)	893	_	78	_
Balance at June 30, 2015	11,635,480	\$ 12	\$181,028	\$ (2,175) \$ (4,719) \$ (11,344	\$162,802
Balance at December 31, 2015	11,535,212	\$ 12	\$179,707	\$ (2,006) \$ (5,227) \$ (12,735	\$159,751
Net increase in net assets resulting from operations	_		_	8,909	(4,728) (2,862) 1,319
Issuance of common stock under dividend reinvestment plan	12,937		142	_		_	142
Repurchases of common stock	_	_	(16)	_	_		(16)
Distributions declared	_			(7,966) —	_	(7,966)
Balance at June 30, 2016	11,548,149	\$ 12	\$179,833	\$ (1,063) \$ (9,955) \$ (15,597	\$153,230

See Notes to Consolidated Financial Statements

Consolidated Statements of Cash Flows (Unaudited)

	For the Sine Ended June 30, 2016	x Months 2015
Cash flows from operating activities:	2010	2015
Net increase in net assets resulting from operations	\$1,319	\$5,590
Adjustments to reconcile net increase in net assets resulting from operations to net cash	+ -,>	+ - ,- > -
provided by (used in) operating activities:		
Amortization of debt issuance costs	306	523
Net realized loss on investments	2,862	259
Net unrealized depreciation (appreciation) on investments	4,728	(18)
Purchase of investments	(31,687)	(71,933)
Principal payments received on investments	40,466	36,577
Proceeds from sale of investments	935	_
Changes in assets and liabilities:		
Net decrease (increase) in investments in money market funds	285	(307)
Net decrease in restricted investments in money market funds	1,091	1,064
Increase in interest receivable	(372)	(194)
Increase in end-of-term payments	(1,510)	(673)
(Decrease) increase in unearned income	(278)	97
(Increase) decrease in other assets	(19)	431
(Decrease) increase in other accrued expenses	(28)	38
Increase in base management fee payable	21	11
Decrease in incentive fee payable	(1)	(77)
Net cash provided by (used in) operating activities	18,118	(28,612)
Cash flows from financing activities:		
Proceeds from issuance of common stock, net of offering costs		26,659
Repayment of Asset-Backed Notes	(14,546)	(14,191)
Advances on credit facility	_	26,000
Distributions paid	(7,820)	(7,003)
Repurchase of common stock	(16)	
Debt issuance costs	(221)	
Net cash (used in) provided by financing activities	(22,603)	31,465
Net (decrease) increase in cash	(4,485)	2,853
Cash:		
Beginning of period	20,765	8,417
End of period	\$16,280	\$11,270

Supplemental disclosure of cash flow information:

Cash paid for interest	\$2,722	\$2,317
Supplemental non-cash investing and financing activities:		
Warrant investments received and recorded as unearned income	\$149	\$485
Distributions payable	\$3,984	\$4,014
End-of-term payments receivable	\$6,570	\$4,458

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

June 30, 2016

			Principal	Cost of Investments	Fair
Portfolio Company (1)	Sector	Type of Investment $(3)(4)(7)(9)(10)$	Amount	(6)	Value
Debt Investments — 148 Debt Investments — Life Argos Therapeutics, Inc.	e Science — 33.0%	(8) Term Loan (9.25% cash (Libor +			
(2)(5)	Biotechnology	8.75%; Floor 9.25%; Ceiling 10.75%), 5.00% ETP, Due 10/1/18)	\$ 5,000	\$ 4,953	\$4,953
		Term Loan (9.25% cash (Libor + 8.75%; Floor 9.25%; Ceiling 10.75%), 5.00% ETP, Due 3/1/19)	5,000	4,962	4,962
New Haven Pharmaceuticals, Inc. (2)(11)	Biotechnology	Term Loan (11.50% cash (Libor + 11.00%; Floor	1,301	1,293	1,293
		11.50%), 11.42% ETP, Due 3/1/19) Term Loan (11.50% cash (Libor + 11.00%; Floor 11.50%), 11.42% ETP, Due 3/1/19)	434	431	431
		Term Loan (10.50% cash (Libor + 10.00%; Floor 10.50%), 6.10% ETP, Due 3/1/19)	2,000	1,988	1,988
		Term Loan (10.00% cash (Libor + 9.50%; Floor 10.00%), 4.00% ETP, Due 4/1/19)	6,265	6,198	6,198
Palatin Technologies, Inc. (2)(5)	Biotechnology	Term Loan (9.00% cash (Libor + 8.50%; Floor 9.00%), 5.00% ETP, Due 1/1/19)	5,000	4,950	4,950
		Term Loan (9.00% cash (Libor + 8.50%; Floor 9.00%), 5.00% ETP, Due 8/1/19)	5,000	4,946	4,946
Sample6, Inc. (2)	Biotechnology	Term Loan (9.50% cash (Libor + 9.00%; Floor	1,361	1,357	1,357

		9.50%; Ceiling 11.00%), 4.00% ETP, Due 4/1/18) Term Loan (9.50% cash (Libor + 9.00%; Floor 9.50%; Ceiling 11.00%), 4.00% ETP,	827	823	823
		Due 4/1/18) Term Loan (9.50% cash (Libor + 9.00%; Floor 9.50%; Ceiling 11.00%), 4.00% ETP,	2,500	2,485	2,485
Lantos Technologies, Inc. (2)	Medical Device	Due 4/1/18) Term Loan (11.50% cash (Libor + 10.50%; Floor 11.50%), 5.00% ETP, Due 2/1/18)	2,917	2,881	2,881
Mederi Therapeutics, Inc. (2)	Medical Device	Term Loan (12.29% cash (Libor + 11.82%), 4.00% ETP, Due 7/1/17)	2,121	2,105	2,105
		Term Loan (12.29% cash (Libor + 11.82%), 4.00% ETP, Due 7/1/17)	2,121	2,105	2,105
NinePoint Medical, Inc. (2)	Medical Device	Term Loan (9.25% cash (Libor + 8.75%; Floor	5,000	4,952	4,952
		9.25%), 4.50% ETP, Due 3/1/19) Term Loan (9.25% cash (Libor + 8.75%; Floor	2,500	2,470	2,470
Tryton Medical, Inc. (2)	Medical Device	9.25%), 4.50% ETP, Due 3/1/19) Term Loan (10.66% cash (Prime + 7.16%), 2.50% ETP, Due 9/1/16)	1,688	1,685	1,685
Total Debt Investments – Life Science Debt Investments — Technology — 83.8% (8				50,584	50,584
Ekahau, Inc. (2)	Communications	Term Loan (11.75% cash, 2.50% ETP, Due 2/1/17)	390	388	388
		Term Loan (11.75% cash, 2.50% ETP, Due 2/1/17)	130	130	130
mBlox, Inc. (2)	Communications	Term Loan (11.50% cash (Libor + 11.00%; Floor 11.50%; Ceiling 13.00%), 3.40% ETP, Due 7/1/18)	4,464	4,446	4,446
		Term Loan (11.50% cash (Libor + 11.00%; Floor 11.50%; Ceiling 13.00%), 3.40%	4,464	4,446	4,446
Additech, Inc. (2)	Consumer-related Technologies	ETP, Due 7/1/18) Term Loan (11.75% cash (Libor + 11.25%; Floor 11.75%; Ceiling 13.25%), 4.00%	2,083	2,060	2,060
		ETP, Due 7/1/18) Term Loan (11.75% cash (Libor + 11.25%; Floor	2,500	2,470	2,470

Edgar Filing: Horizon Technology Finance Corp - Form 10-Q

		11.75%; Ceiling 13.25%), 4.00% ETP, Due 1/1/19)			
Gwynnie Bee, Inc. (2)	Consumer-related	Term Loan (11.00% cash (Libor + 10.50%; Floor	1,067	1,051	1,051
	Technologies	11.00%; Ceiling 12.50%), 2.00%			
		ETP, Due 11/1/17)			
		Term Loan (11.00% cash (Libor +	633	620	620
		10.50%; Floor	033	020	020
		11.00%; Ceiling 12.50%), 2.00%			
		ETP, Due 2/1/18)			
		Term Loan (11.00% cash (Libor + 10.50%; Floor	700	689	689
		11.00%; Ceiling 12.50%), 2.00%			
		ETP, Due 4/1/18)			
Rhapsody International,	Consumer-related	Term Loan (11.00% cash (Libor +	7,500	7,306	7,306
Inc. (2)	Technologies	10.50%; Floor	7,500	7,500	7,500
	Consuman malatad	11.00%), 3.00% ETP, Due 10/1/19)			
SavingStar, Inc. (2)	Consumer-related Technologies	Term Loan (10.90% cash (Libor + 10.40%; Floor	3,000	2,952	2,952
	recimologies	10.90%), 3.00% ETP, Due 6/1/19)			
		Term Loan (10.90% cash (Libor +	2 000	1.060	1.060
		10.40%; Floor	2,000	1,960	1,960
		10.90%), 3.00% ETP, Due 3/1/20)			
MediaBrix, Inc. (2)	Internet and Media	Term Loan (11.50% cash (Libor + 11.00%; Floor	4,000	3,960	3,960
		11.50%), 3.00% ETP, Due 1/1/20)			
Zinio Holdings, LLC (2)	Internet and Media	Term Loan (11.75% cash (Libor +	4,000	3,962	3,962
Zimo Holdings, EEC (2)	mornet and Media	11.25%; F100f	1,000	5,702	5,702
		11.75%), 4.00% ETP, Due 2/1/20)			

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

June 30, 2016

			Principal		Fair
Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)(9)(10)	Amount	Investments (6)	Value
The NanoSteel Company, Inc. (2)	Materials	Term Loan (10.00% cash (Libor + 9.50%; Floor	5,000	4,928	4,928
		10.00%), 5.00% ETP, Due 7/1/19) Term Loan (10.00% cash (Libor + 9.50%; Floor 10.00%), 5.00% ETP, Due 7/1/19)	2,500	2,464	2,464
		Term Loan (10.00% cash (Libor + 9.50%; Floor 10.00%), 5.00% ETP, Due 1/1/20)	2,500	2,458	2,458
Nanocomp Technologies, Inc. (2)	Networking	Term Loan (11.50% cash, 3.00% ETP, Due 11/1/17)	524	520	520
		Term Loan (11.50% cash (Libor + 11.00%; Floor	3,000	2,944	2,944
Powerhouse Dynamics, Inc. (2)	Power Management	11.50%), 3.00% ETP, Due 4/1/20) Term Loan (11.20% cash (Libor + 10.70%; Floor	2,500	2,463	2,463
Avalanche Technology, Inc. (2)	Semiconductors	11.20%), 3.00% ETP, Due 3/1/19) Term Loan (10.00% cash (Libor + 9.25%; Floor 10.00%;	1,044	1,041	1,041
		Ceiling 11.75%), 2.40% ETP, Due 4/1/17) Term Loan (10.00% cash (Libor + 9.25%; Floor 10.00%; Ceiling 11.75%), 2.40% ETP, Due	1,700	1,695	1,695
		10/1/18) Term Loan (10.00% cash (Libor + 9.25%; Floor 10.00%; Ceiling 11.75%), 2.00% ETP, Due	1,905	1,867	1,867
InVisage Technologies, Inc. (2)	Semiconductors	2/1/19) Term Loan (12.00% cash (Libor + 11.50%; Floor	1,955	1,913	1,913

		12.00%; Ceiling 14.00%), 2.50% ETP, Due 12/31/16) Term Loan (12.00% cash (Libor + 11.50%; Floor 12.00%; Ceiling 14.00%), 2.50% ETP,	822	811	811
Luxtera, Inc. (2)	Semiconductors	Due 12/31/16) Term Loan (10.25% cash (Libor + 9.75%; Floor 10.25%; Ceiling 12.25%), 13.00% ETP, Due	1,140	1,126	1,126
		7/1/17) Term Loan (10.25% cash (Libor + 9.75%; Floor 10.25%; Ceiling 12.25%), 13.00% ETP, Due	636	634	634
		7/1/17) Term Loan (9.00% cash (Libor + 8.50%; Floor 9.00%), 4.50% ETP, Due 12/1/18)	833	829	829
		Term Loan (9.00% cash (Libor + 8.50%; Floor 9.00%),	833	828	828
		4.50% ETP, Due 12/1/18) Term Loan (9.50% cash (Libor + 9.00%; Floor 9.50%), 4.50% ETP, Due 11/1/19)	2,000	1,989	1,989
Xtera Communications, Inc. (5)	Semiconductors	Term Loan (12.50% cash, 17.50% ETP, Due 7/31/16)	3,056	3,047	3,047
iiic. (3)		Term Loan (12.50% cash, 17.50% ETP, Due 7/31/16)	849	847	847
Bridge2 Solutions, Inc.	Software	Term Loan (11.50% cash (Libor + 11.00%; Floor	4,000	3,971	3,971
		11.50%; Ceiling 14.50%), 2.00% ETP, Due 7/1/19) Term Loan (11.50% cash (Libor + 11.00%; Floor 11.50%; Ceiling 14.50%), 2.00% ETP, Due 1/1/20)	1,000	996	996
ControlScan, Inc. (2)	Software	Term Loan (10.70% cash (Libor + 10.25%),	4,500	4,406	4,406
Crowdstar, Inc. (2)	Software	3.00% ETP, Due 7/1/20) Term Loan (10.75% cash (Libor + 10.25%; Floor 10.75%), 3.00% ETP, Due 9/1/18)	1,636	1,616	1,616
Decisyon, Inc. (2)	Software	Term Loan (12.78% cash (Libor + 12.308%; Floor	1,523	1,520	1,434
		12.50%), 6.50% ETP, Due 10/1/17) Term Loan (12.78% cash (Libor + 12.308%; Floor 12.50%), 6.50% ETP, Due 1/1/18)	833	703	663
Digital Signal Corporation	Software	Term Loan (10.72% cash (Libor + 10.25%; Floor	1,500	1,463	1,214
		10.43%), 5.00% ETP, Due 7/1/19)	1,500	1,463	1,214

Edgar Filing: Horizon Technology Finance Corp - Form 10-Q

Education Elements, Inc. (2)	Software	Term Loan (10.72% cash (Libor + 10.25%; Floor 10.43%), 5.00% ETP, Due 7/1/19) Term Loan (10.50% cash (Libor + 10.00%; Floor 10.50%), 4.00% ETP, Due 1/1/19)	2,000	1,973	1,973
		Term Loan (10.50% cash (Libor + 10.00%; Floor	1,500	1,474	1,474
Netuitive, Inc.	Software	10.50%), 4.00% ETP, Due 8/1/19) Term Loan (12.72% cash (Libor + 12.25%; Floor 12.50%), 3.33% ETP, Due 9/1/17)	663	662	662
Nomi Corporation (11)	Software	Term Loan (10.62% cash (Libor + 10.15%; Floor	3,184	3,148	850
		10.35%), 2.00% ETP, Due 1/1/20) Term Loan (10.62% cash (Libor + 10.15%; Floor 10.35%), 2.00% ETP, Due 1/1/20)	3,184	3,148	850
ScoreBig, Inc. (2)	Software	Term Loan (10.50% cash (Libor + 10.00%; Floor	3,403	3,327	3,327
		10.50%), 4.00% ETP, Due 4/1/19) Term Loan (10.50% cash (Libor + 10.00%; Floor	3,403	3,357	3,357
		10.50%), 4.00% ETP, Due 4/1/19) Term Loan (10.50% cash (Libor + 10.00%; Floor	2,000	1,948	1,948

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

June 30, 2016

D (S II) G (1)	G.	T (2) (4) (T) (2) (40)	Principal	Cost of Investments	Fair
Portfolio Company (1)	Sector	Type of Investment $(3)(4)(7)(9)(10)$	Amount	(6)	Value
SIGNiX, Inc. (2)	Software	10.50%), 4.00% ETP, Due 3/1/20) Term Loan (11.50% cash (Libor + 11.00%; Floor 11.50%), Due 8/1/18)	2,600	2,524	2,235
SilkRoad Technology, Inc. (2)	Software	Term Loan (10.85% cash (Libor + 10.35%; Floor 10.85%; Ceiling 12.85%), 3.00% ETP, Due 6/1/19)	7,500	7,445	7,445
Skyword, Inc.	Software	Term Loan (11.45% cash (Libor + 10.95%; Floor 11.45%), 3.00% ETP, Due 8/1/19)	4,000	3,934	3,934
Social Intelligence Corp. (2)	Software	Term Loan (11.00% cash (Libor + 10.50%; Floor 11.00%; Ceiling 13.00%), 3.50% ETP,	484	473	467
Sys-Tech Solutions, Inc. (2)	Software	Due 12/1/17) Term Loan (11.65% cash (Libor + 11.15%; Floor 11.65%; Ceiling 12.65%), 4.50% ETP,	4,000	3,976	3,976
		Due 3/1/18) Term Loan (11.65% cash (Libor + 11.15%; Floor 11.65%; Ceiling 12.65%), 9.00% ETP, Due 5/1/18)	3,667	3,640	3,640
VBrick Systems, Inc. (2)	Software	Term Loan (11.50% cash (Libor + 11.00%; Floor 11.50%; Ceiling 13.50%), 5.00% ETP, Due 7/1/17)	1,300	1,291	1,291
Vidsys, Inc. (2)	Software	Term Loan (13.00% cash, 7.58% ETP, Due 12/1/17)	2,770	2,770	2,770
xTech Holdings, Inc. (2)	Software	Term Loan (11.00% cash (Libor + 10.50%; Floor 11.00%), 3.00% ETP, Due 4/1/19)	1,833	1,808	1,808
		=======================================			

		Term Loan (11.00% cash (Libor + 10.50%; Floor 11.00%), 3.00% ETP, Due 3/1/20)	2,000	1,966	1,966
Total Debt Investments — Technology Debt Investments — Cleantech — 6.1% (8)				133,846	128,331
Renmatix, Inc. (2)	Alternative Energy	Term Loan (10.25% cash, Due 10/1/16)	684	684	684
Rypos, Inc. (2)	Energy Efficiency	Term Loan (12.02% cash, 4.25% ETP, Due 6/1/17)	1,995	1,978	1,978
		Term Loan (12.02% cash, 4.25% ETP, Due 1/1/18)	852	841	841
Lehigh Technologies, Inc. (2)	Waste Recycling	Term Loan (10.19% cash (Libor + 9.72%), 6.75% ETP, Due 8/1/19)	3,000	2,964	2,964
		Term Loan (10.19% cash (Libor + 9.72%), 6.75% ETP, Due 8/1/19)	3,000	2,978	2,978
Total Debt Investments — Cleantech Debt Investments —				9,445	9,445
Healthcare information and services — 25.2% (8)					
Interleukin Genetics, Inc. (2)(5)	Diagnostics	Term Loan (9.00% cash (Libor + 8.50%; Floor 9.00%) 4.50% ETP, Due 10/1/18)	4,500	4,403	4,156
LifePrint Group, Inc. (2)	Diagnostics	Term Loan (11.00% cash (Libor + 10.50%; Floor	1,800	1,775	1,775
	Od	11.00%; Ceiling 12.50%), 3.00% ETP, Due 1/1/18)			
Watermark Medical, Inc. (2)	Other Healthcare	Term Loan (10.00% cash (Libor + 9.50%; Floor 10.00%; Ceiling 11.00%); 4.00% ETP, Due	3,208	3,203	3,203
		4/1/18) Term Loan (10.00% cash (Libor + 9.50%; Floor 10.00%;	3,208	3,203	3,203
		Ceiling 11.00%); 4.00% ETP, Due 4/1/18) Term Loan (10.00% cash (Libor + 9.50%; Floor 10.00%;	1,250	1,248	1,248
		Ceiling 11.00%); 4.00% ETP, Due 4/1/18)			
MedAvante, Inc. (2)	Software	Term Loan (9.75% cash (Libor + 9.25%; Floor 9.75%), 4.00% ETP, Due 1/1/19)	3,000	2,964	2,964
		Term Loan (9.75% cash (Libor + 9.25%; Floor	3,000	2,964	2,964
		9.75%), 4.00% ETP, Due 1/1/19) Term Loan (9.75% cash (Libor + 9.25%; Floor	4,000	3,943	3,943

Edgar Filing: Horizon Technology Finance Corp - Form 10-Q

		9.75%), 4.00% ETP, Due 7/1/19)			
Medsphere Systems Corporation (2)	Software	Term Loan (10.50% cash (Libor + 10.00%; Floor	5,000	4,933	4,933
•		10.50%), 7.00% ETP, Due 7/1/19) Term Loan (10.50% cash (Libor + 10.00%; Floor	2,500	2,466	2,466
Recondo Technology, Inc. (2)	Software	10.50%), 7.00% ETP, Due 7/1/19) Term Loan (11.50% cash (Libor + 11.00%; Floor	1,038	1,035	1,035
		11.50%), 6.60% ETP, Due 12/1/17) Term Loan (11.00% cash (Libor + 10.50%; Floor 11.00%), 4.50% ETP, Due 12/1/17)	1,875	1,870	1,870
		Term Loan (10.50% cash (Libor + 10.00%; Floor 10.50%), 2.75% ETP, Due 12/1/17)	1,875	1,872	1,872
		Term Loan (10.50% cash (Libor + 10.00%; Floor 10.50%), 2.50% ETP, Due 1/1/19)	3,000	2,971	2,971
Total Debt Investments —					
Healthcare information and services				38,850	38,603
Total Debt Investments				232,725	226,963

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

June 30, 2016

Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)(9)(10)	Cost of Investments (6)	Fair Value
Warrant Investments — 3.3% (8) Warrants — Life Science — 0.2 (8)				
ACT Biotech Corporation	Biotechnology	1,521,820 Preferred Stock Warrants	83	
Argos Therapeutics, Inc. (2)(5)	Biotechnology	33,112 Common Stock Warrants	33	4
Celsion Corporation (5)	Biotechnology	5,708 Common Stock Warrants	15	_
Inotek Pharmaceuticals Corporation (5)	Biotechnology	28,204 Common Stock Warrants	17	43
New Haven Pharmaceuticals, Inc. (2)	Biotechnology	103,982 Preferred Stock Warrants	88	1
Nivalis Therapeutics, Inc. (5)	Biotechnology	18,534 Common Stock Warrants	122	_
Ocera Therapeutics, Inc. (2)(5)	Biotechnology	6,491 Common Stock Warrants	6	
Palatin Technologies, Inc. (2)(5)	Biotechnology	608,058 Common Stock Warrants	51	
Revance Therapeutics, Inc. (5)	Biotechnology	34,377 Common Stock Warrants	68	47
Sample6, Inc. (2)	Biotechnology	351,018 Preferred Stock Warrants	45	30
Sunesis Pharmaceuticals, Inc. (5)	Biotechnology	12,302 Common Stock Warrants	5	
AccuVein Inc. (2)	Medical Device	75,769 Preferred Stock Warrants	24	28
Direct Flow Medical, Inc.	Medical Device	176,922 Preferred Stock Warrants	144	_
EnteroMedics, Inc. (5)	Medical Device	9,402 Common Stock Warrants	347	
IntegenX, Inc. (2)	Medical Device	170,646 Preferred Stock Warrants	34	25
Lantos Technologies, Inc. (2)	Medical Device	1,287,817 Preferred Stock Warrants	38	40
Mederi Therapeutics, Inc. (2)	Medical Device	248,736 Preferred Stock Warrants	26	38
Mitralign, Inc. (2)	Medical Device	641,909 Preferred Stock Warrants	52	36
NinePoint Medical, Inc. (2)	Medical Device	566,038 Preferred Stock Warrants	33	32
OraMetrix, Inc. (2)	Medical Device	812,348 Preferred Stock Warrants	78	_
Tryton Medical, Inc. (2)	Medical Device	122,362 Preferred Stock Warrants	15	10
ViOptix, Inc.	Medical Device	375,763 Preferred Stock Warrants	13	
Total Warrants — Life Science			1,337	334
Warrants — Technology — 2.5				
Ekahau, Inc. (2)	Communications	978,261 Preferred Stock Warrants	33	19

OpenPeak, Inc.	Communications	18,997 Common Stock Warrants	89	_
Additech, Inc. (2)	Consumer-related Technologies	150,000 Preferred Stock Warrants	33	26
Everyday Health, Inc. (5)	Consumer-related Technologies	43,783 Common Stock Warrants	69	8
Gwynnie Bee, Inc. (2)	Consumer-related Technologies	268,591 Preferred Stock Warrants	68	689
If(we), Inc.	Consumer-related Technologies	190,868 Preferred Stock Warrants	27	61
Rhapsody International Inc. (2)	Consumer-related Technologies	852,273 Common Stock Warrants	164	146
SavingStar, Inc. (2)	Consumer-related Technologies	98,860 Preferred Stock Warrants	59	57
XIOtech, Inc.	Data Storage	2,217,979 Preferred Stock Warrants	22	
SimpleTuition, Inc.	Internet and media	189,573 Preferred Stock Warrants	63	64
The NanoSteel Company, Inc. (2)	Materials	147,424 Preferred Stock Warrants	93	88
IntelePeer, Inc.	Networking	141,549 Common Stock Warrants	39	26
Nanocomp Technologies, Inc. (2)	Networking	681,819 Preferred Stock Warrants	54	48
Aquion Energy, Inc.	Power Management	115,051 Preferred Stock Warrants	7	60
Powerhouse Dynamics, Inc. (2)	Power Management	290,698 Preferred Stock Warrants	28	27
Avalanche Technology, Inc. (2)	Semiconductors	202,602 Preferred Stock Warrants	101	41
eASIC Corporation (2)	Semiconductors	40,445 Preferred Stock Warrants	25	27
InVisage Technologies, Inc. (2)	Semiconductors	395,009 Preferred Stock Warrants	48	43
Kaminario, Inc.	Semiconductors	1,087,203 Preferred Stock Warrants	59	61
Luxtera, Inc.(2)	Semiconductors	2,508,671 Preferred Stock Warrants	49	100
Soraa, Inc. (2)	Semiconductors	180,000 Preferred Stock Warrants	80	411
Xtera Communications, Inc. (5)	Semiconductors	37,831 Common Stock Warrants	205	
Bolt Solutions Inc. (2)	Software	202,892 Preferred Stock Warrants	113	109
Bridge2 Solutions, Inc.	Software	75,458 Common Stock Warrants	18	333
Clarabridge, Inc.	Software	53,486 Preferred Stock Warrants	14	81
ControlScan, Inc. (2)	Software	2,295,918 Preferred Stock Warrants	19	19
Crowdstar, Inc. (2)	Software	75,428 Preferred Stock Warrants	14	11
Decisyon, Inc. (2)	Software	82,967 Common Stock Warrants	46	
Digital Signal Corporation	Software	85,308 Common Stock Warrants	32	
Education Elements, Inc. (2)	Software	238,122 Preferred Stock Warrants	28	22
Lotame Solutions, Inc. (2)	Software	288,115 Preferred Stock Warrants	22	267
Netuitive, Inc.	Software	41,569 Common Stock Warrants	48	
Nomi Corporation	Software	2,535,864 Preferred Stock Warrants	_	—
Riv Data Corp. (2)	Software	237,361 Preferred Stock Warrants	12	10
ScoreBig, Inc. (2)	Software	879,014 Preferred Stock Warrants	88	45
SIGNiX, Inc. (2)	Software	72,166 Preferred Stock Warrants	88	85
Skyword, Inc.	Software	301,056 Preferred Stock Warrants	48	46
SpringCM, Inc. (2)	Software	2,385,686 Preferred Stock Warrants	55	118

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

June 30, 2016

			Cost of	Fair
Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)(9)(10)	Investments (6)	Value
Sys-Tech Solutions, Inc.	Software	375,000 Preferred Stock Warrants	242	555
Vidsys, Inc.	Software	85,399 Preferred Stock Warrants	23	21
Visage Mobile, Inc.	Software	1,692,047 Preferred Stock Warrants	19	
xTech Holdings, Inc. (2)	Software	158,730 Preferred Stock Warrants	43	43
Total Warrants — Technology			2,387	3,768
Warrants — Cleantech — 0.19	6 (8)			
Renmatix, Inc.	Alternative Energy	53,022 Preferred Stock Warrants	68	
Semprius, Inc.	Alternative Energy	519,981 Preferred Stock Warrants	25	20
Rypos, Inc. (2)	Energy Efficiency	5,627 Preferred Stock Warrants	44	21
Tigo Energy, Inc. (2)	Energy Efficiency	804,604 Preferred Stock Warrants	100	108
Lehigh Technologies, Inc. (2)	Waste Recycling	272,727 Preferred Stock Warrants	33	32
Total Warrants — Cleantech			270	181
Warrants — Healthcare				
information and services — 0.5	5%			
(8)				
Accumetrics, Inc.	Diagnostics	100,928 Preferred Stock Warrants	107	63
Candescent Health, Inc. (2)	Diagnostics	519,991 Preferred Stock Warrants	378	
Helomics Corporation	Diagnostics	13,461 Common Stock Warrants	73	
Interleukin Genetics, Inc.	Diagnostics	2,492,523 Common Stock Warrants	112	88
(2)(5)	Diagnostics	2,492,323 Common Stock Warrants	112	00
LifePrint Group, Inc. (2)	Diagnostics	49,000 Preferred Stock Warrants	29	1
ProterixBio, Inc. (2)	Diagnostics	3,156 Common Stock Warrants	54	
Singulex, Inc.	Other Healthcare	293,632 Preferred Stock Warrants	44	44
Verity Solutions Group, Inc.	Other Healthcare	300,360 Preferred Stock Warrants	100	35
Watermark Medical, Inc. (2)	Other Healthcare	27,373 Preferred Stock Warrants	74	61
MedAvante, Inc. (2)	Software	114,285 Preferred Stock Warrants	66	64
Medsphere Systems Corporation (2)	Software	7,097,791 Preferred Stock Warrants	60	194
Recondo Technology, Inc. (2)	Software	556,796 Preferred Stock Warrants	95	193
Total Warrants — Healthcare			1,192	743
information and services Total Warrants			5 196	5,026
Total warrants			5,186	3,020

Other Investments — 0.4% (8)				
ZetrOZ, Inc.	Medical Device	Royalty Agreement	375	400
Vette Technology, LLC	Data Storage	Royalty Agreement Due 4/18/2019	4,375	200
Total Other Investments			4,750	600
Equity — 0.4% (8)				
Insmed Incorporated (5)	Biotechnology	33,208 Common Stock	238	328
Revance Therapeutics, Inc.(5)	Biotechnology	4,861 Common Stock	73	66
Sunesis Pharmaceuticals, Inc. (5)	Biotechnology	78,493 Common Stock	83	43
SnagAJob.com, Inc.	Consumer-related Technologies	82,974 Common Stock	9	83
Decisyon, Inc.	Software	3,573,173 Common Stock	157	157
Total Equity			560	677
Total Portfolio Investment Assets — 152.2%			\$ 243,221	\$233,266

⁽¹⁾ All investments of the Company are in entities which are organized under the laws of the United States and have a principal place of business in the United States.

(3) All investments are less than 5% ownership of the class and ownership of the portfolio company.

All interest is payable in cash due monthly in arrears, unless otherwise indicated, and applies only to the Company's debt investments. Interest rate is the annual interest rate on the debt investment and does not include end-of-term payments ("ETPs") and any additional fees related to the investments, such as deferred interest, commitment fees or prepayment fees. All debt investments are at fixed rates for the term of the debt investment, unless otherwise indicated. Debt investments based on LIBOR are based on one-month LIBOR. For each debt investment, the current interest rate in effect as of June 30, 2016 is provided.

- (5) Portfolio company is a public company.
- (6) For debt investments, represents principal balance less unearned income.
- (7) Warrants, Equity and Other Investments are non-income producing.
- (8) Value as a percent of net assets.

The Company did not have any non-qualifying assets under Section 55(a) of the Investment Company Act of 1940, as amended (the "1940 Act"), as of June 30, 2016. Under the 1940 Act, the Company may not acquire any non-qualifying assets unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company's total assets.

(10) ETPs are contractual fixed-interest payments due in cash at the maturity date of the applicable debt investment, including upon any prepayment, and are a fixed percentage of the original principal balance of the debt investments unless otherwise noted. Interest will accrue during the life of the debt investment on each ETP and will be recognized as non-cash income until it is actually paid. Therefore, a portion of the incentive fee the

⁽²⁾ Has been pledged as collateral under the Key Facility.

Company may pay its Advisor will be based on income that the Company has not yet received in cash.

(11)Debt investment is on non-accrual status at June 30, 2016.

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

December 31, 2015

Portfolio Company (1)	Sector	Type of Investment (3)(4)(7)(9)(10)	Principal Amount	Cost of Investments (6)	Fair Value
Debt Investments — 151.6		4. (0)			
Debt Investments — Life S Argos Therapeutics, Inc. (2)(5)	Biotechnology	6 (8) Term Loan (9.25% cash (Libor + 8.75%; Floor 9.25%;	\$ 5,000	\$ 4,944	\$4,944
		Ceiling 10.75%), 5.00% ETP, Due 10/1/18)			
		Term Loan (9.25% cash (Libor + 8.75%; Floor 9.25%;	5,000	4,954	4,954
		Ceiling 10.75%), 5.00% ETP, Due			
New Haven Pharmaceuticals, Inc. (2)	Biotechnology	3/1/19) Term Loan (11.50% cash (Libor + 11.00%; Floor	1,301	1,293	1,293
		11.50%), 11.42% ETP, Due 3/1/19) Term Loan (11.50% cash (Libor + 11.00%; Floor	434	431	431
		11.50%), 11.42% ETP, Due 3/1/19) Term Loan (10.50% cash (Libor + 10.00%; Floor	2,000	1,987	1,987
		10.50%), 6.10% ETP, Due 3/1/19) Term Loan (10.00% cash (Libor + 9.50%; Floor	6,265	6,190	6,190
Palatin Technologies, Inc. (2)(5)	Biotechnology	10.00%), 4.00% ETP, Due 4/1/19) Term Loan (9.00% cash (Libor + 8.50%; Floor	5,000	4,939	4,939
		9.00%), 5.00% ETP, Due 1/1/19) Term Loan (9.00% cash (Libor + 8.50%; Floor	5,000	4,937	4,937
Sample6, Inc. (2)	Biotechnology	9.00%), 5.00% ETP, Due 8/1/19) Term Loan (9.50% cash (Libor + 9.00%; Floor 9.50%; Ceiling 11.00%), 4.00% ETP,	1,555	1,550	1,550
		Due 4/1/18)			

		Term Loan (9.50% cash (Libor + 9.00%; Floor 9.50%; Ceiling 11.00%), 4.00% ETP,	945	940	940
		Due 4/1/18)			
		Term Loan (9.50% cash (Libor + 9.00%;	2.500	2.481	2,481
		Floor	2,300	2,401	2,101
		9.50%; Ceiling 11.00%), 4.00% ETP,			
Comment Discourse and a de-		Due 4/1/18)			
Sunesis Pharmaceuticals, Inc. (2)(5)	Biotechnology	Term Loan (8.95% cash, 4.65% ETP, Due 10/1/16)	545	544	544